DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB:CBIS.ob), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce final negotiations to target an immediate European expansion with opportune acquisitions & licensing deals. This new set of deals is designed to bring to bring new products, revenues, and executive management to the company’s growing operations. The target European company has already created its footprint distributing its products in the European Markets and around the world while meeting Cannabis Science’s standards to ensure the utmost quality control and stringent procedures.
This potential acquisition will give Cannabis Science additional products and revenues along with some outstanding continued growth with a good mix of all three product lines and Cannabis Science formulations in Europe and around the world. Continuing in the current focus with the FDA, OTC markets and dispensaries, the Company expects to expand all its current formulations along with the new European line of products the Company is negotiating to purchase. These new European resources will enhance our internal operations and are a vital piece of fulfilling our business model to bring our full line of both Cannabis Science Brand pharmaceutical and over the counter products to Europe. This acquisition can give Cannabis Science additional resources needed for global distribution channels for their products as well as expanding the market potential for the new European line to be acquired.
